Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease
Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Alzheimer's Disease
Intervention: Rosiglitazone XR (extended release) oral tablets (Drug); Placebo (Drug)
Phase: Phase 2
Status: Terminated
Sponsored by: GlaxoSmithKline Official(s) and/or principal investigator(s): GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
Summary
Clinical features in patients with the familial early onset forms and the sporadic forms of
Alzheimers disease are similar, although the course of deterioration may be different. It
would be very informative to examine the drug response of patients with Alzheimers disease
by a certain genotype to find evidence favouring genotype-specific drug responses that may
indicate genetically defined phenotypic differences in alzheimers disease.
Clinical Details
Official title: A Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilisation and Cognition in Subjects With Mild to Moderate Alzheimers Disease (AD)
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Change in global and regional cerebral glucose metabolism/Cerebral Metabolic Rate for glucose (CMRglu) as measured by the ratio of Ki to K1
Secondary outcome: Changes in global and regional CMRglu as measured by [18F]FDG uptake.Global changes in brain structure from baseline as measured by structural MRI from baseline.Vital signs and ECGs.
Eligibility
Minimum age: 50 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Meets the National Institute of Neurological and Communicative Diseases and
Stroke/Alzheimers Disease and Related Disorders Association (NINCDS-ADRDA) criteria
for Alzheimers disease, regardless of date of diagnosis relative to study entry date.
- Has an Alzheimers disease status of mild to moderate, as classified by a Mini Mental
State Examination (MMSE) score of 16 - 26 inclusive at screening.
- Post-menopausal females defined as menopause is defined as >6 months without
menstrual period with an appropriate clinical profile, e. g. age appropriate, history
of vasomotor symptoms. However if indicated this should be confirmed by oestradiol
and FSH levels consistent with menopause (according to local laboratory ranges).
- Women who are on HRT (hormone replacement therapy) treatment, and have not been
confirmed as post-menopausal should be advised to use contraception.
- Has a permanent caregiver who is willing to attend all visits, oversee the subjects
compliance with protocol-specified procedures and study medication, and report on
subjects status. (Subjects living alone or in a nursing home are not eligible).
Exclusion Criteria:
- Has a history of or suffers from claustrophobia.
- Is unable to lie comfortably on a bed inside a PET camera with their head in the
field of view for at least 60 minutes as assessed by physical examination and medical
history (e. g. back pain, arthritis).
- Has a history or presence of other neurological or other medical conditions that may
influence the outcome or analysis of the PET scan results. Examples of such
conditions include, but are not limited to stroke, traumatic brain injury, epilepsy
or space occupying lesions.
- History of Type I or Type II diabetes mellitus.
- Fasting plasma glucose level >126 mg/dL (>7. 0 mmol/L) or HbA1c >6. 2%.
- History or clinical/laboratory evidence of moderate congestive heart failure defined
by the New York Heart Association criteria (class II-IV.
Locations and Contacts
GSK Investigational Site, Cambridge, Cambridgeshire CB2 2EF, United Kingdom
Additional Information
Starting date: December 2004
Last updated: January 10, 2013
|